Biodesix INC Form 4 insider transactions

Jack W Schuler, a 10% owner of Biodesix Inc, purchased 15,000 shares of common stock on August 12, 2026 for $24.47 per share.

Jack W Schuler, a 10% owner of Biodesix Inc, purchased 27,600 shares of common stock on August 10, 2026.

John Patience, Director and Chairman of Bio-De-Six Inc., reported a transaction involving the acquisition of 1,361 restricted stock units.

John Patience, Director and Chairman of Bio-De-Sign Inc., reported transactions involving restricted stock units and common stock.

Biodesix Chief Development Officer Gary Pestano reported the acquisition of common stock from RSU vesting and subsequent sale of shares to cover tax obligations.

Biodesix Chief Commercial Officer Kieran O'Kane reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

BIODESIX CFO Robin Harper Cowie reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Biodesix Chief Accounting Officer Chris Vazquez sold 211 shares of common stock to cover taxes following the vesting of restricted stock units.

BIODESIX President and CEO Scott Hutton reported the vesting of restricted stock units and a subsequent tax-related sale of common stock.

Biodesix Chief Commercial Officer Kieran O'Kane reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Biodesix's Chief Accounting Officer, Chris Vazquez, reported the sale of 101 common shares at an average price of $10.0841 to cover tax obligations related to RSU vesting.

Biodesix President and CEO Scott Hutton disclosed the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

BIODESIX Inc.'s CFO, Robin Harper Cowie, reported the acquisition of common stock through RSU vesting and a subsequent sale to cover tax obligations.

BIODESIX Chief Development Officer Gary Pestano reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Jack W. Schuler, a Director and 10% Owner of Biodesix Inc., increased his indirect beneficial ownership by purchasing 100,000 shares of common stock across two transactions in late January 2026.

Biodesix Director and 10% Owner Jack W. Schuler acquired 82,465 shares of common stock through a pre-arranged trading plan.

Biodesix Chief Accounting Officer Chris Vazquez reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

BIODESIX Chief Development Officer Gary Pestano reported the acquisition of common stock from RSU vesting and subsequent sale of shares to cover tax obligations.

Biodesix Chief Commercial Officer Kieran O'Kane reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

BIODESIX CEO Scott Hutton acquired shares through RSU vesting and subsequently sold a portion to cover tax liabilities, as disclosed in a recent Form 4 filing.

BIODESIX CFO Robin Harper Cowie reported the acquisition of common stock from RSU vesting and subsequent sale of shares to cover tax liabilities.

BIODESIX Director Jean M. Franchi reported the acquisition of Restricted Stock Units and Stock Options, aligning her interests with the company's future performance.

Biodesix Director Matthew Strobeck was granted 6,804 Restricted Stock Units and options to purchase 6,354 shares of common stock on January 2, 2026.

Biodesix Chairman John Patience reported new grants of restricted stock units and stock options, alongside the conversion of previously vested RSUs into common stock.

Biodesix Director Hany Massarany was granted 7,484 Restricted Stock Units and options for 6,354 shares of common stock.

Biodesix Director and 10% Owner Lawrence T. Kennedy Jr. acquired 5,443 restricted stock units and 6,354 stock options, aligning his interests with shareholders.

BIODESIX Director Jon Faiz Kayyem was granted 5,443 Restricted Stock Units and options to purchase 6,354 shares of common stock.

Biodesix's Chief Development Officer, Gary Pestano, was granted 26,000 stock options with an exercise price of $6.46, vesting over four years.

BIODESIX Chief Commercial Officer Kieran O'Kane was granted 27,000 stock options with an exercise price of $6.46, vesting over four years.

BIODESIX Inc. President and CEO Scott Hutton was granted 97,000 stock options with a $6.46 exercise price, vesting over four years.